Literature DB >> 16012140

An agenda to combat substance abuse.

Steven A Schroeder1.   

Abstract

Despite their huge health toll, substance abuse disorders remain underappreciated and underfunded. Reasons include stigma, tolerance of personal choices, acceptance of youthful experimentation, pessimism about treatment efficacy, fragmented and weak leadership, powerful tobacco and alcohol industries, underinvestment in research, and difficult patients. Positive signs include declining prevalence rates, successful counter-marketing campaigns, changing public attitudes, new scientific discoveries that could yield new treatments, and effective new organizations. Further progress will require better treatment, more research, better education of health professionals, more nongovernmental support, and stronger leadership. Policy changes regarding each of the three substance groups are indicated, as are reforms in the criminal justice and educational systems.

Entities:  

Mesh:

Year:  2005        PMID: 16012140     DOI: 10.1377/hlthaff.24.4.1005

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  4 in total

1.  The effect of substance abuse treatment on Medicaid expenditures among general assistance welfare clients in Washington state.

Authors:  Thomas M Wickizer; Antoinette Krupski; Kenneth D Stark; David Mancuso; Kevin Campbell
Journal:  Milbank Q       Date:  2006       Impact factor: 4.911

2.  A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

Authors:  Traci R Rieckmann; Anne E Kovas; Bentson H McFarland; Amanda J Abraham
Journal:  J Subst Abuse Treat       Date:  2011-08-06

3.  Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.

Authors:  Todd Molfenter; Carol Sherbeck; Mark Zehner; Andy Quanbeck; Dennis McCarty; Jee-Seon Kim; Sandy Starr
Journal:  Subst Abuse Treat Prev Policy       Date:  2015-03-28

4.  Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.

Authors:  Todd Molfenter; Hannah K Knudsen; Randy Brown; Nora Jacobson; Julie Horst; Mark Van Etten; Jee-Seon Kim; Eric Haram; Elizabeth Collier; Sanford Starr; Alexander Toy; Lynn Madden
Journal:  Implement Sci       Date:  2017-11-15       Impact factor: 7.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.